Anti-tuberculosis Therapeutics Market Analysis and Forecast to 2031: By Drug Class (Isoniazid, Rifampin, Others), End-User (Hospitals, Clinics, Government Agencies, Others), and Region

Anti-tuberculosis (TB) therapeutics are drugs used to treat TB infection. The most common TB drug is isoniazid, which is used to treat both active and latent TB infections. Other TB drugs include rifampicin, ethambutol, and pyrazinamide. These drugs are typically used in combination to treat active TB infection.

Key Trends

The key trends in anti-tuberculosis therapeutics technology are the development of new drugs and the use of new delivery methods. The development of new drugs is important because it allows for the treatment of resistant strains of tuberculosis. The use of new delivery methods is important because it allows for the delivery of drugs to the lungs more effectively.

Key Drivers

The key drivers of the global anti-tuberculosis therapeutics market are the increasing incidence of tuberculosis, the availability of new and effective treatments, and the increasing awareness of the disease.

The incidence of tuberculosis has been increasing globally in recent years. According to the World Health Organization, there were nearly 10.4 million new cases of tuberculosis in 2019, and approximately 1.7 million people died from the disease.

The availability of new and effective treatments for tuberculosis is another key driver of the market. In the past, the only available treatment for tuberculosis was a long course of antibiotics, which often had to be taken for up to six months.

The increasing awareness of tuberculosis is also a key driver of the market. In the past, tuberculosis was often seen as a disease that only affected people in developing countries.

Restraints & Challenges

The key restraints and challenges in the Anti-tuberculosis Therapeutics market are the increasing number of drug-resistant strains of tuberculosis and the lack of new and effective drugs to treat the disease.

Drug-resistant strains of tuberculosis are a major challenge for the treatment of the disease, as they are difficult to treat and can lead to relapse.

There is a need for new and effective drugs to treat tuberculosis, as the existing drugs are not effective against all strains of the disease.

There is also a need for better diagnostic tools to identify drug-resistant strains of tuberculosis.

Market Segments

The anti-tuberculosis therapeutics market is segmented by drug class, end-user, and region. By drug class, the market is classified into isoniazid, rifampin, and others. Based on the end-user, it is bifurcated into hospitals, clinics, government agencies, and others. Region-wise, the market is segmented into North America, Europe, Asia Pacific, and the rest of the World.

Key Players

The anti-tuberculosis therapeutics market includes players such as Lupin Limited, Macleods Pharmaceuticals Ltd, Otsuka Pharmaceutical Co. Ltd, Johnson and Johnson, Sequella Inc., Novartis AG, Akorn Operating Company LLC, Fresenius SE & Co. KGaA, Viatris Inc., AstraZeneca, and others.

Why GIS?

Table of Contents

Chapter 1. Market Introduction
1.1. Objectives of the Study
1.2. Market Definition and Research & Scope
1.3. Research Methodologies
1.4. Market Estimation Techniques

Chapter 2. Executive Summary
2.1. Summary
2.2. Key Highlights of the Market

Chapter 3. Anti-tuberculosis Therapeutics Market Outlook
3.1. Anti-tuberculosis Therapeutics Market Segmentation
3.2. Market Dynamics
3.2.1. Market Drivers
3.2.1.1. Driver 1
3.2.1.2. Driver 2
3.2.1.3. Driver 3
3.2.2. Market Restraints
3.2.2.1. Restraint 1
3.2.2.2. Restraint 2
3.2.3. Market Opportunities
3.2.3.1. Opportunity 1
3.2.3.2. Opportunity 2
3.3. Porter’s Five Forces Analysis
3.3.1. Threat of New Entrants
3.3.2. Threat of Substitutes
3.3.3. Bargaining Power of Buyers
3.3.4. Bargaining Power of Supplier
3.3.5. Competitive Rivalry
3.4. PESTLE Analysis
3.5. Value Chain Analysis
3.5.1. Raw Material Suppliers
3.5.2. Manufacturers
3.5.3. Wholesalers and/or Retailers
3.6. Impact of the Russia and Ukraine War on the Global Anti-tuberculosis Therapeutics Market

Chapter 4. Economic Impact of COVID-19
4.1. Overall Impact of COVID-19
4.2. Impact of COVID On the Global Anti-tuberculosis Therapeutics Market
4.3. Economic Impact Analysis

Chapter 5. Anti-tuberculosis Therapeutics Market by Drug Class
5.1. Market Overview
5.2. Isoniazid
5.2.1. Market Size and Forecast, 2021-2031 ($Million)
5.2.2. Market Size and Forecast, by Region, 2021-2031 ($Million)
5.3. Rifampin
5.3.1. Market Size and Forecast, 2021-2031 ($Million)
5.3.2. Market Size and Forecast, by Region, 2021-2031 ($Million)
5.4. Others
5.4.1. Market Size and Forecast, 2021-2031 ($Million)
5.4.2. Market Size and Forecast, by Region, 2021-2031 ($Million)

Chapter 6. Anti-tuberculosis Therapeutics Market by End-User
6.1. Market Overview
6.2. Hospitals
6.2.1. Market Size and Forecast, 2021-2031 ($Million)
6.2.2. Market Size and Forecast, by Region, 2021-2031 ($Million)
6.3. Clinics
6.3.1. Market Size and Forecast, 2021-2031 ($Million)
6.3.2. Market Size and Forecast, by Region, 2021-2031 ($Million)
6.4. Government Agencies
6.4.1. Market Size and Forecast, 2021-2031 ($Million)
6.4.2. Market Size and Forecast, by Region, 2021-2031 ($Million)
6.5. Others
6.5.1. Market Size and Forecast, 2021-2031 ($Million)
6.5.2. Market Size and Forecast, by Region, 2021-2031 ($Million)

Chapter 7. Anti-tuberculosis Therapeutics Market, by Region
7.1. Overview
7.2. North America
7.2.1. Key Market Trends and Opportunities
7.2.2. North America Anti-tuberculosis Therapeutics Market Size and Forecast by Drug Class, 2021-2031, ($Million)
7.2.3. North America Anti-tuberculosis Therapeutics Market Size and Forecast by End-User, 2021-2031, ($Million)
7.2.4. North America Anti-tuberculosis Therapeutics Market Size and Forecast by Country, 2021-2031, ($Million)
7.2.5. The U.S.
7.2.5.1. The U.S. Anti-tuberculosis Therapeutics Market Size and Forecast by Drug Class, 2021-2031, ($Million)
7.2.5.2. The U.S. Anti-tuberculosis Therapeutics Market Size and Forecast by End-User, 2021-2031, ($Million)
7.2.6. Canada
7.2.6.1. Canada Anti-tuberculosis Therapeutics Market Size and Forecast by Drug Class, 2021-2031, ($Million)
7.2.6.2. Canada Anti-tuberculosis Therapeutics Market Size and Forecast by End-User, 2021-2031, ($Million)
7.2.7. Mexico
7.2.7.1. Mexico Anti-tuberculosis Therapeutics Market Size and Forecast by Drug Class, 2021-2031, ($Million)
7.2.7.2. Mexico Anti-tuberculosis Therapeutics Market Size and Forecast by End-User, 2021-2031, ($Million)

7.3. Europe
7.3.1. Key Market Trends and Opportunities
7.3.2. Europe Anti-tuberculosis Therapeutics Market Size and Forecast by Drug Class, 2021-2031, ($Million)
7.3.3. Europe Anti-tuberculosis Therapeutics Market Size and Forecast by End-User, 2021-2031, ($Million)
7.3.4. Europe Anti-tuberculosis Therapeutics Market Size and Forecast by Country, 2021-2031, ($Million)
7.3.5. Germany
7.3.5.1. Germany Anti-tuberculosis Therapeutics Market Size and Forecast by Drug Class, 2021-2031, ($Million)
7.3.5.2. Germany Anti-tuberculosis Therapeutics Market Size and Forecast by End-User, 2021-2031, ($Million)
7.3.6. France
7.3.6.1. France Anti-tuberculosis Therapeutics Market Size and Forecast by Drug Class, 2021-2031, ($Million)
7.3.6.2. France Anti-tuberculosis Therapeutics Market Size and Forecast by End-User, 2021-2031, ($Million)
7.3.7. U.K.
7.3.7.1. U.K. Anti-tuberculosis Therapeutics Market Size and Forecast by Drug Class, 2021-2031, ($Million)
7.3.7.2. U.K. Anti-tuberculosis Therapeutics Market Size and Forecast by End-User, 2021-2031, ($Million)
7.3.8. Spain
7.3.8.1. Spain Anti-tuberculosis Therapeutics Market Size and Forecast by Drug Class, 2021-2031, ($Million)
7.3.8.2. Spain Anti-tuberculosis Therapeutics Market Size and Forecast by End-User, 2021-2031, ($Million)
7.3.9. Italy
7.3.9.1. Italy Anti-tuberculosis Therapeutics Market Size and Forecast by Drug Class, 2021-2031, ($Million)
7.3.9.2. Italy Anti-tuberculosis Therapeutics Market Size and Forecast by End-User, 2021-2031, ($Million)
7.3.10. Rest of Europe
7.3.10.1. Rest of Europe Anti-tuberculosis Therapeutics Market Size and Forecast by Drug Class, 2021-2031, ($Million)
7.3.10.2. Rest of Europe Anti-tuberculosis Therapeutics Market Size and Forecast by End-User, 2021-2031, ($Million)

7.4. Asia-Pacific
7.4.1. Key Market Trends and Opportunities
7.4.2. Asia-Pacific Anti-tuberculosis Therapeutics Market Size and Forecast by Country, 2021-2031, ($Million)
7.4.3. Asia-Pacific Anti-tuberculosis Therapeutics Market Size and Forecast by Drug Class, 2021-2031, ($Million)
7.4.4. Asia-Pacific Anti-tuberculosis Therapeutics Market Size and Forecast by End-User, 2021-2031, ($Million)
7.4.5. China
7.4.5.1. China Anti-tuberculosis Therapeutics Market Size and Forecast by Drug Class, 2021-2031, ($Million)
7.4.5.2. China Anti-tuberculosis Therapeutics Market Size and Forecast by End-User, 2021-2031, ($Million)
7.4.6. India
7.4.6.1. India Anti-tuberculosis Therapeutics Market Size and Forecast by Drug Class, 2021-2031, ($Million)
7.4.6.2. India Anti-tuberculosis Therapeutics Market Size and Forecast by End-User, 2021-2031, ($Million)
7.4.7. Japan
7.4.7.1. Japan Anti-tuberculosis Therapeutics Market Size and Forecast by Drug Class, 2021-2031, ($Million)
7.4.7.2. Japan Anti-tuberculosis Therapeutics Market Size and Forecast by End-User, 2021-2031, ($Million)
7.4.8. South Korea
7.4.8.1. South Korea Anti-tuberculosis Therapeutics Market Size and Forecast by Drug Class, 2021-2031, ($Million)
7.4.8.2. South Korea Anti-tuberculosis Therapeutics Market Size and Forecast by End-User, 2021-2031, ($Million)
7.4.9. Rest of APAC
7.4.9.1. Rest of APAC Anti-tuberculosis Therapeutics Market Size and Forecast by Drug Class, 2021-2031, ($Million)
7.4.9.2. Rest of APAC Anti-tuberculosis Therapeutics Market Size and Forecast by End-User, 2021-2031, ($Million)

7.5. Rest of the World
7.5.1. Key Market Trends and Opportunities
7.5.2. Rest of the World Anti-tuberculosis Therapeutics Market Size and Forecast by Drug Class, 2021-2031, ($Million)
7.5.3. Rest of the World Anti-tuberculosis Therapeutics Market Size and Forecast by End-User, 2021-2031, ($Million)
7.5.4. Rest of the World Anti-tuberculosis Therapeutics Market Size and Forecast by Country, 2021-2031, ($Million)
7.5.5. Latin America
7.5.5.1. Latin America Anti-tuberculosis Therapeutics Market Size and Forecast by Drug Class, 2021-2031, ($Million)
7.5.5.2. Latin America Anti-tuberculosis Therapeutics Market Size and Forecast by End-User, 2021-2031, ($Million)
7.5.6. Middle East
7.5.6.1. Middle East Anti-tuberculosis Therapeutics Market Size and Forecast by Drug Class, 2021-2031, ($Million)
7.5.6.2. Middle East Anti-tuberculosis Therapeutics Market Size and Forecast by End-User, 2021-2031, ($Million)
7.5.7. Africa
7.5.7.1. Africa Anti-tuberculosis Therapeutics Market Size and Forecast by Drug Class, 2021-2031, ($Million)
7.5.7.2. Africa Anti-tuberculosis Therapeutics Market Size and Forecast by End-User, 2021-2031, ($Million)

Chapter 8. Competitive Landscape
8.1. Market Overview
8.2. Market Share Analysis/Key Player Positioning
8.3. Developmental Strategy Benchmarking
8.3.1. New Product Development
8.3.2. Product Launches
8.3.3. Business Expansions
8.3.4. Partnerships, Joint Ventures, and Collaborations
8.3.5. Mergers and Acquisitions

Chapter 9. Company Profiles
9.1. Lupin Limited
9.1.1. Company Snapshot
9.1.2. Financial Performance
9.1.3. Product Offerings
9.1.4. Key Strategic Initiatives
9.1.5. SWOT Analysis
9.2. Macleods Pharmaceuticals Ltd
9.2.1. Company Snapshot
9.2.2. Financial Performance
9.2.3. Product Offerings
9.2.4. Key Strategic Initiatives
9.2.5. SWOT Analysis
9.3. Otsuka Pharmaceutical Co. Ltd
9.3.1. Company Snapshot
9.3.2. Financial Performance
9.3.3. Product Offerings
9.3.4. Key Strategic Initiatives
9.3.5. SWOT Analysis
9.4. Johnson and Johnson
9.4.1. Company Snapshot
9.4.2. Financial Performance
9.4.3. Product Offerings
9.4.4. Key Strategic Initiatives
9.4.5. SWOT Analysis
9.5. Sequella Inc.
9.5.1. Company Snapshot
9.5.2. Financial Performance
9.5.3. Product Offerings
9.5.4. Key Strategic Initiatives
9.5.5. SWOT Analysis
9.6. Novartis AG
9.6.1. Company Snapshot
9.6.2. Financial Performance
9.6.3. Product Offerings
9.6.4. Key Strategic Initiatives
9.6.5. SWOT Analysis
9.7. Akorn Operating Company LLC
9.7.1. Company Snapshot
9.7.2. Financial Performance
9.7.3. Product Offerings
9.7.4. Key Strategic Initiatives
9.7.5. SWOT Analysis
9.8. Fresenius SE & Co. KGaA
9.8.1. Company Snapshot
9.8.2. Financial Performance
9.8.3. Product Offerings
9.8.4. Key Strategic Initiatives
9.8.5. SWOT Analysis
9.9. Viatris Inc.
9.9.1. Company Snapshot
9.9.2. Financial Performance
9.9.3. Product Offerings
9.9.4. Key Strategic Initiatives
9.9.5. SWOT Analysis
9.10. AstraZeneca
9.10.1. Company Snapshot
9.10.2. Financial Performance
9.10.3. Product Offerings
9.10.4. Key Strategic Initiatives
9.10.5. SWOT Analysis

*The list of companies is subject to change during the final compilation of the report

 

 

Market Segmentation

By Drug Class

  • Isoniazid
  • Rifampin
  • Others

By End-User

  • Hospitals
  • Clinics
  • Government Agencies
  • Others

By Region

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • UK
    • France
    • Germany
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • Japan
    • South Korea
    • Rest of APAC
  • Rest of the World
    • Latin America
    • Middle East
    • Africa

Order this Report

Have questions about the scope of the report ?

Have specific requirements ?

Budget Constraints ?

Related Reports

The global soft tissue anchors market was valued…
The global micro surgical robot market was valued…
The global brain cancer diagnostics market was valued…